LONDON: Diaceutics PLC (AIM: DXRX), a technology provider for pharmaceutical and biotech companies, announced strong first-half revenue growth driven by increased demand for its precision medicine commercialization services.
Revenue rose 22% on a constant currency basis to £14.6 million ($18.9 million) in H1 2025, marking a three-year compound annual growth rate of 25%. Recurring revenue now represents 70% of total income, with annual recurring revenue (ARR) climbing 16% to £16.4 million ($21.3 million). The company’s order book stands at £29.4 million ($38.2 million), including £8.8 million ($11.4 million) contracted for H2 delivery.
CEO Ryan Keeling attributed the results to “strong operational and commercial execution,” citing expanded customer adoption despite global economic uncertainties. Diaceutics secured its eighth enterprise-wide agreement during the period, bringing total ARR from such deals to £10.1 million ($13.1 million). The company now serves 74 therapeutic brands across 43 clients, up 17% year-over-year.
Diaceutics maintained a debt-free balance sheet with £10.4 million ($13.5 million) in cash. The board expressed confidence in meeting full-year growth and profitability targets, citing 79% revenue visibility for 2025.
Keeling emphasized the company’s role in helping clients “improve patient access to therapy, capture lost revenue and increase profitability.” Diaceutics works with 18 of the world’s top 20 pharmaceutical firms.